The Value of no Evidence of Disease (NED) in Intermediate‐Stage Hepatocellular Carcinoma After TACE: A Real‐World Study DOI
Lujun Shen,

Yiquan Jiang,

Yueqian Wu

и другие.

Liver International, Год журнала: 2025, Номер 45(5)

Опубликована: Апрель 15, 2025

ABSTRACT Background and Aims One‐third of patients with intermediate‐stage hepatocellular carcinoma (HCC) can achieve imaging‐based no evidence disease (NED) during treatment after transarterial chemoembolization (TACE) sequential therapies; however, its temporal dynamics, contributing factors prognostic value remain unknown. Methods The longitudinal data 1665 HCC from Sun Yat‐sen University Cancer Center were included as a derivation cohort; 414 three external medical centers served the validation cohort. Image‐Only NED is defined based on imaging exams while having serum level alpha‐fetoprotein (AFP) above upper limit; Image‐Bio pertains to an additional achievement normal AFP. A semi‐Markov multistate model was adopted identify transitions between intermediate states, which unreached, NED, recurrence death. time‐dependent Cox proportional hazards for overall survival (OS) utilised evaluate dynamic states. Results percentage who reached Image 35.2% 24.7% in cohort, 37.4% 31.4% proportion peaked by end second year since initial declined gradually. Patients had higher risk compared subgroup ( p < 0.05). With unreached reference, multivariate showed (HR 0.44; 95% CI 0.33–0.59) 0.26; 0.20–0.33) significant states that predict distinct OS HCC, further confirmed multi‐centre Conclusions Our study highlights clinical course demonstrates significance TACE. recommended serve important endpoint management HCC.

Язык: Английский

Dynamic prognostication and treatment planning for hepatocellular carcinoma: A machine learning-enhanced survival study using multi-centric data DOI
Lujun Shen,

Yiquan Jiang,

Linbin Lu

и другие.

The Innovation Medicine, Год журнала: 2025, Номер unknown, С. 100125 - 100125

Опубликована: Янв. 1, 2025

<p>A reliable system for dynamic prognostication and management of hepatocellular carcinoma (HCC) is urgently needed but currently unavailable. In our previous work, we developed a machine learning algorithm termed "Survival Path" (raw-SP) to enhance with longitudinal survival data. However, the model was limited intermediate stage HCC patients, it faced risk overfitting due path proliferation. this study, novel framework incorporating nodal fusion techniques mitigate overfitting, expanded model's applicability all stages patients. A post-fusion map (fusion-SP) containing 14 different paths built, which demonstrated superior or non-inferior accuracy in prognosis prediction patients compared raw-SP, as well traditional staging systems within first 15 months since initial diagnosis large-scale derivation, internal external validation cohorts. Subgroup analysis showed fusion-SP performance other models among BCLC C disease tumor burden above up-to-seven criteria. Under fusion-SP, distinct optimal combination treatment strategies advanced-stage at key nodes were uncovered, where frameworks fall short. The could serve robust tool facilitating planning HCC. Moreover, streamlined methodology holds potential be applied across various types cancers.</p>

Язык: Английский

Процитировано

0

The Value of no Evidence of Disease (NED) in Intermediate‐Stage Hepatocellular Carcinoma After TACE: A Real‐World Study DOI
Lujun Shen,

Yiquan Jiang,

Yueqian Wu

и другие.

Liver International, Год журнала: 2025, Номер 45(5)

Опубликована: Апрель 15, 2025

ABSTRACT Background and Aims One‐third of patients with intermediate‐stage hepatocellular carcinoma (HCC) can achieve imaging‐based no evidence disease (NED) during treatment after transarterial chemoembolization (TACE) sequential therapies; however, its temporal dynamics, contributing factors prognostic value remain unknown. Methods The longitudinal data 1665 HCC from Sun Yat‐sen University Cancer Center were included as a derivation cohort; 414 three external medical centers served the validation cohort. Image‐Only NED is defined based on imaging exams while having serum level alpha‐fetoprotein (AFP) above upper limit; Image‐Bio pertains to an additional achievement normal AFP. A semi‐Markov multistate model was adopted identify transitions between intermediate states, which unreached, NED, recurrence death. time‐dependent Cox proportional hazards for overall survival (OS) utilised evaluate dynamic states. Results percentage who reached Image 35.2% 24.7% in cohort, 37.4% 31.4% proportion peaked by end second year since initial declined gradually. Patients had higher risk compared subgroup ( p < 0.05). With unreached reference, multivariate showed (HR 0.44; 95% CI 0.33–0.59) 0.26; 0.20–0.33) significant states that predict distinct OS HCC, further confirmed multi‐centre Conclusions Our study highlights clinical course demonstrates significance TACE. recommended serve important endpoint management HCC.

Язык: Английский

Процитировано

0